These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 29659672)

  • 1. Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma.
    Abou-Alfa GK; Qin S; Ryoo BY; Lu SN; Yen CJ; Feng YH; Lim HY; Izzo F; Colombo M; Sarker D; Bolondi L; Vaccaro G; Harris WP; Chen Z; Hubner RA; Meyer T; Sun W; Harding JJ; Hollywood EM; Ma J; Wan PJ; Ly M; Bomalaski J; Johnston A; Lin CC; Chao Y; Chen LT
    Ann Oncol; 2018 Jun; 29(6):1402-1408. PubMed ID: 29659672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of pegylated arginine deiminase and modified FOLFOX6 in patients with advanced hepatocellular carcinoma: Results of an international, single-arm, phase 2 study.
    Harding JJ; Yang TS; Chen YY; Feng YH; Yen CJ; Ho CL; Huang WT; El Dika I; Akce M; Tan B; Cohen SA; Meyer T; Sarker D; Lee DW; Ryoo BY; Lim HY; Johnston A; Bomalaski JS; O'Reilly EM; Qin S; Abou-Alfa GK
    Cancer; 2021 Dec; 127(24):4585-4593. PubMed ID: 34415578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase 1 study of ADI-PEG 20 and modified FOLFOX6 in patients with advanced hepatocellular carcinoma and other gastrointestinal malignancies.
    Harding JJ; Do RK; Dika IE; Hollywood E; Uhlitskykh K; Valentino E; Wan P; Hamilton C; Feng X; Johnston A; Bomalaski J; Li CF; O'Reilly EM; Abou-Alfa GK
    Cancer Chemother Pharmacol; 2018 Sep; 82(3):429-440. PubMed ID: 29971467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients.
    Yang TS; Lu SN; Chao Y; Sheen IS; Lin CC; Wang TE; Chen SC; Wang JH; Liao LY; Thomson JA; Wang-Peng J; Chen PJ; Chen LT
    Br J Cancer; 2010 Sep; 103(7):954-60. PubMed ID: 20808309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma.
    Kang YK; Yau T; Park JW; Lim HY; Lee TY; Obi S; Chan SL; Qin S; Kim RD; Casey M; Chen C; Bhattacharyya H; Williams JA; Valota O; Chakrabarti D; Kudo M
    Ann Oncol; 2015 Dec; 26(12):2457-63. PubMed ID: 26386123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1-Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial.
    Szlosarek PW; Steele JP; Nolan L; Gilligan D; Taylor P; Spicer J; Lind M; Mitra S; Shamash J; Phillips MM; Luong P; Payne S; Hillman P; Ellis S; Szyszko T; Dancey G; Butcher L; Beck S; Avril NE; Thomson J; Johnston A; Tomsa M; Lawrence C; Schmid P; Crook T; Wu BW; Bomalaski JS; Lemoine N; Sheaff MT; Rudd RM; Fennell D; Hackshaw A
    JAMA Oncol; 2017 Jan; 3(1):58-66. PubMed ID: 27584578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies.
    Izzo F; Marra P; Beneduce G; Castello G; Vallone P; De Rosa V; Cremona F; Ensor CM; Holtsberg FW; Bomalaski JS; Clark MA; Ng C; Curley SA
    J Clin Oncol; 2004 May; 22(10):1815-22. PubMed ID: 15143074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma.
    Ott PA; Carvajal RD; Pandit-Taskar N; Jungbluth AA; Hoffman EW; Wu BW; Bomalaski JS; Venhaus R; Pan L; Old LJ; Pavlick AC; Wolchok JD
    Invest New Drugs; 2013 Apr; 31(2):425-34. PubMed ID: 22864522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Down-regulation of argininosuccinate synthetase is associated with cisplatin resistance in hepatocellular carcinoma cell lines: implications for PEGylated arginine deiminase combination therapy.
    McAlpine JA; Lu HT; Wu KC; Knowles SK; Thomson JA
    BMC Cancer; 2014 Aug; 14():621. PubMed ID: 25164070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.
    Llovet JM; Decaens T; Raoul JL; Boucher E; Kudo M; Chang C; Kang YK; Assenat E; Lim HY; Boige V; Mathurin P; Fartoux L; Lin DY; Bruix J; Poon RT; Sherman M; Blanc JF; Finn RS; Tak WY; Chao Y; Ezzeddine R; Liu D; Walters I; Park JW
    J Clin Oncol; 2013 Oct; 31(28):3509-16. PubMed ID: 23980090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 1 trial of ADI-PEG 20 and liposomal doxorubicin in patients with metastatic solid tumors.
    Yao S; Janku F; Koenig K; Tsimberidou AM; Piha-Paul SA; Shi N; Stewart J; Johnston A; Bomalaski J; Meric-Bernstam F; Fu S
    Cancer Med; 2022 Jan; 11(2):340-347. PubMed ID: 34841717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo.
    Ensor CM; Holtsberg FW; Bomalaski JS; Clark MA
    Cancer Res; 2002 Oct; 62(19):5443-50. PubMed ID: 12359751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regression of hepatocellular cancer in a patient treated with arginine deiminase.
    Curley SA; Bomalaski JS; Ensor CM; Holtsberg FW; Clark MA
    Hepatogastroenterology; 2003; 50(53):1214-6. PubMed ID: 14571701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma.
    Glazer ES; Piccirillo M; Albino V; Di Giacomo R; Palaia R; Mastro AA; Beneduce G; Castello G; De Rosa V; Petrillo A; Ascierto PA; Curley SA; Izzo F
    J Clin Oncol; 2010 May; 28(13):2220-6. PubMed ID: 20351325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase I Study of Pegylated Arginine Deiminase (Pegargiminase), Cisplatin, and Pemetrexed in Argininosuccinate Synthetase 1-Deficient Recurrent High-grade Glioma.
    Hall PE; Lewis R; Syed N; Shaffer R; Evanson J; Ellis S; Williams M; Feng X; Johnston A; Thomson JA; Harris FP; Jena R; Matys T; Jefferies S; Smith K; Wu BW; Bomalaski JS; Crook T; O'Neill K; Paraskevopoulos D; Khadeir RS; Sheaff M; Pacey S; Plowman PN; Szlosarek PW
    Clin Cancer Res; 2019 May; 25(9):2708-2716. PubMed ID: 30796035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 1b study of pegylated arginine deiminase (ADI-PEG 20) plus Pembrolizumab in advanced solid cancers.
    Chang KY; Chiang NJ; Wu SY; Yen CJ; Chen SH; Yeh YM; Li CF; Feng X; Wu K; Johnston A; Bomalaski JS; Wu BW; Gao J; Subudhi SK; Kaseb AO; Blando JM; Yadav SS; Szlosarek PW; Chen LT
    Oncoimmunology; 2021; 10(1):1943253. PubMed ID: 34290906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted cellular metabolism for cancer chemotherapy with recombinant arginine-degrading enzymes.
    Kuo MT; Savaraj N; Feun LG
    Oncotarget; 2010 Aug; 1(4):246-51. PubMed ID: 21152246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Randomized Clinical Trial.
    Yoon SM; Ryoo BY; Lee SJ; Kim JH; Shin JH; An JH; Lee HC; Lim YS
    JAMA Oncol; 2018 May; 4(5):661-669. PubMed ID: 29543938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial.
    Zhu AX; Kudo M; Assenat E; Cattan S; Kang YK; Lim HY; Poon RT; Blanc JF; Vogel A; Chen CL; Dorval E; Peck-Radosavljevic M; Santoro A; Daniele B; Furuse J; Jappe A; Perraud K; Anak O; Sellami DB; Chen LT
    JAMA; 2014 Jul; 312(1):57-67. PubMed ID: 25058218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pegylated arginine deiminase lowers hepatitis C viral titers and inhibits nitric oxide synthesis.
    Izzo F; Montella M; Orlando AP; Nasti G; Beneduce G; Castello G; Cremona F; Ensor CM; Holtzberg FW; Bomalaski JS; Clark MA; Curley SA; Orlando R; Scordino F; Korba BE
    J Gastroenterol Hepatol; 2007 Jan; 22(1):86-91. PubMed ID: 17201887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.